Novartis Bolsters NASH Pipeline with a Deal with Conatus
By Subham Nandi
Pharma Deals Review: Vol 2017 Issue 1 (Table of Contents)
Published: 18 Jan-2017
DOI: 10.3833/pdr.v2017.i1.2218 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Novartis adds heat to the highly competitive non-alcoholic steatohepatitis (NASH) market with a deal with Conatus Pharmaceutical to co-develop emricasan, an oral first-in-class pan-caspase inhibitor being evaluated for NASH fibrosis and cirrhosis in a deal worth US$722 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS